Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laurent Chambonneau

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Pharmaceutical Statistics|May 25, 2023
Bayesian borrowing from historical control data in a vaccine efficacy trialLin Peng, Jing Jin, Laurent Chambonneau, et al.
Clinical Therapeutics|September 1, 2004
A randomized, open-label study of the immunogenicity and reactogenicity of three lots of a combined typhoid fever/hepatitis A vaccine in healthy adultsMicha Loebermann, Herwig Kollaritsch, Tom Ziegler, et al.
Journal of Travel Medicine|December 14, 2005
Combined typhoid fever and hepatitis A vaccine: comparison of immunogenicity and safety to concomitant monovalent vaccine over 3 yearsDavid Overbosch, François Peyron, Nicole Picot, et al.
The Journal of Infectious Diseases|July 16, 2016
Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2-16 Years in Asia and Latin AmericaGustavo Olivera-Botello, Laurent Coudeville, Karen Fanouillere, et al.
The Journal of Infectious Diseases|June 26, 2021
Analysis of Neutralizing Antibodies as a Correlate of Instantaneous Risk of Hospitalized Dengue in Placebo Recipients of Dengue Vaccine Efficacy TrialsYing Huang, Brian D Williamson, Zoe Moodie, et al.
The Pediatric Infectious Disease Journal|March 25, 2008
Age-specific prevalence of dengue antibodies in Bangkok infants and childrenKrisana Pengsaa, Kriengsak Limkittikul, Christine Luxemburger, et al.
The Journal of Infectious Diseases|November 4, 2006
Dengue virus infections in the first 2 years of life and the kinetics of transplacentally transferred dengue neutralizing antibodies in thai childrenKrisana Pengsaa, Christine Luxemburger, Arunee Sabchareon, et al.
Vaccine|April 25, 2006
Innate and adaptive cellular immunity in flavivirus-naïve human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3)Violette Sanchez, Sophie Gimenez, Brian Tomlinson, et al.
Transactions of the Royal Society of Tropical Medicine and Hygiene|December 28, 2020
Immunobridging efficacy of a tetravalent dengue vaccine against dengue and against hospitalized dengue from children/adolescents to adults in highly endemic countriesYing Huang, Zoe Moodie, Michal Juraska, et al.
Vaccine|August 18, 2015
Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised studyJoseph Torresi, Leon G Heron, Ming Qiao, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Pharmaceutical Statistics|May 25, 2023
Bayesian borrowing from historical control data in a vaccine efficacy trialLin Peng, Jing Jin, Laurent Chambonneau, et al.
Clinical Therapeutics|September 1, 2004
A randomized, open-label study of the immunogenicity and reactogenicity of three lots of a combined typhoid fever/hepatitis A vaccine in healthy adultsMicha Loebermann, Herwig Kollaritsch, Tom Ziegler, et al.
Journal of Travel Medicine|December 14, 2005
Combined typhoid fever and hepatitis A vaccine: comparison of immunogenicity and safety to concomitant monovalent vaccine over 3 yearsDavid Overbosch, François Peyron, Nicole Picot, et al.
The Journal of Infectious Diseases|July 16, 2016
Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2-16 Years in Asia and Latin AmericaGustavo Olivera-Botello, Laurent Coudeville, Karen Fanouillere, et al.
The Journal of Infectious Diseases|June 26, 2021
Analysis of Neutralizing Antibodies as a Correlate of Instantaneous Risk of Hospitalized Dengue in Placebo Recipients of Dengue Vaccine Efficacy TrialsYing Huang, Brian D Williamson, Zoe Moodie, et al.
The Pediatric Infectious Disease Journal|March 25, 2008
Age-specific prevalence of dengue antibodies in Bangkok infants and childrenKrisana Pengsaa, Kriengsak Limkittikul, Christine Luxemburger, et al.
The Journal of Infectious Diseases|November 4, 2006
Dengue virus infections in the first 2 years of life and the kinetics of transplacentally transferred dengue neutralizing antibodies in thai childrenKrisana Pengsaa, Christine Luxemburger, Arunee Sabchareon, et al.
Vaccine|April 25, 2006
Innate and adaptive cellular immunity in flavivirus-naïve human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3)Violette Sanchez, Sophie Gimenez, Brian Tomlinson, et al.
Transactions of the Royal Society of Tropical Medicine and Hygiene|December 28, 2020
Immunobridging efficacy of a tetravalent dengue vaccine against dengue and against hospitalized dengue from children/adolescents to adults in highly endemic countriesYing Huang, Zoe Moodie, Michal Juraska, et al.
Vaccine|August 18, 2015
Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised studyJoseph Torresi, Leon G Heron, Ming Qiao, et al.
Pageof 2